Abstract：
BACKGROUND: Sickle cell disease is a severe genetic disorder, and searching for therapeutic strategies is indispensable for prolonged and improved life for people affected by this condition.
OBJECTIVE: This qualitative systematic review aimed to highlight the therapeutic potential of omega- 3 (n-3) in people with sickle cell disease.
METHODS: The search was performed by combining sickle cell disease and n-3 descriptors in DeCS/ MeSH databases, including Scopus, PubMed, ScienceDirect, Web of Science, and Virtual Health Library. The risk of bias assessment in the primary studies was performed using the Cochrane risk of bias tool for randomized controlled trials. The evidence quality was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.
RESULTS: From the 187 records identified, seven were selected for data collection. Based on the evidence, n-3 supplementation contributes to lower activation of pro-inflammatory biomarkers, improves the concentration of docosahexaenoic and eicosapentaenoic acids in the erythrocyte membrane, provides better hemostatic response, and helps in vaso-occlusive crisis, pain episodes, and hospitalization reduction.
CONCLUSIONS: The findings suggest that n-3 adjuvant therapy favors the clinical and general aspects of people with sickle cell disease.
OBJECTIVE: This qualitative systematic review aimed to highlight the therapeutic potential of omega- 3 (n-3) in people with sickle cell disease.
METHODS: The search was performed by combining sickle cell disease and n-3 descriptors in DeCS/ MeSH databases, including Scopus, PubMed, ScienceDirect, Web of Science, and Virtual Health Library. The risk of bias assessment in the primary studies was performed using the Cochrane risk of bias tool for randomized controlled trials. The evidence quality was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.
RESULTS: From the 187 records identified, seven were selected for data collection. Based on the evidence, n-3 supplementation contributes to lower activation of pro-inflammatory biomarkers, improves the concentration of docosahexaenoic and eicosapentaenoic acids in the erythrocyte membrane, provides better hemostatic response, and helps in vaso-occlusive crisis, pain episodes, and hospitalization reduction.
CONCLUSIONS: The findings suggest that n-3 adjuvant therapy favors the clinical and general aspects of people with sickle cell disease.
摘要：
背景：镰状细胞病是一种严重的遗传性疾病，寻找治疗策略对于延长和改善受这种疾病影响的人的生活是必不可少的。
目的：本系统评价旨在强调omega-3（n-3）在镰状细胞病患者中的治疗潜力。
方法：通过结合DeCS/MeSH数据库中的镰状细胞疾病和n-3描述符进行搜索，包括Scopus,PubMed,ScienceDirect,WebofScience,虚拟健康图书馆主要研究中的偏倚风险评估使用Cochrane偏倚风险工具进行随机对照试验。使用建议评估分级来评估证据质量，发展,和评估（等级）工具。
结果：从确定的187条记录中，选择了7人进行数据收集。根据证据,n-3补充有助于降低促炎生物标志物的激活，提高红细胞膜中二十二碳六烯酸和二十碳五烯酸的浓度，提供更好的止血反应，并有助于血管闭塞危机，疼痛发作,住院减少。
结论：研究结果表明，n-3辅助治疗有利于镰状细胞病患者的临床和一般方面。
目的：本系统评价旨在强调omega-3（n-3）在镰状细胞病患者中的治疗潜力。
方法：通过结合DeCS/MeSH数据库中的镰状细胞疾病和n-3描述符进行搜索，包括Scopus,PubMed,ScienceDirect,WebofScience,虚拟健康图书馆主要研究中的偏倚风险评估使用Cochrane偏倚风险工具进行随机对照试验。使用建议评估分级来评估证据质量，发展,和评估（等级）工具。
结果：从确定的187条记录中，选择了7人进行数据收集。根据证据,n-3补充有助于降低促炎生物标志物的激活，提高红细胞膜中二十二碳六烯酸和二十碳五烯酸的浓度，提供更好的止血反应，并有助于血管闭塞危机，疼痛发作,住院减少。
结论：研究结果表明，n-3辅助治疗有利于镰状细胞病患者的临床和一般方面。
